Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Zhittya Genesis Medicine announces it will begin its Phase I trial in Parkinson's disease in the coming months. When will Venturis start their trial?
Daniel C Montano announces that he will definitely pursue Venturis and seek to seize assets from the company.
Daniel C Montano announces that clinical trials are approved and set to start in Monterrey, Mexico.
Zhittya Genesis Medicine announces that company representatives will be manning a booth and meeting investors face-to-face at The MoneyShow being held in Orlando, FL from June 10 to 12, 2021.
Zhittya Genesis Medicine announces that Dan Montano will be presenting at the Family Offices Investment Summit, in Monaco, being held June 30 to July 2, 2021.
Zhittya Genesis Medicine announces it has won all lawsuits against CardioVascular BioTherapeutics (CVBT-VT) and the court has ruled that Zhittya owns 100% of its own IP relating to FGF-1. Zhittya is proceeding on using FGF-1 for Therapeutic Angiogenesis for 10 separate medical indications.
Zhittya Genesis Medicine announces it has won all lawsuits against CardioVascular BioTherapeutics (CVBT-VT) and the court has ruled that Zhittya owns 100% of its own IP relating to FGF-1. Zhittya is proceeding on using FGF-1 for Therapeutic Angiogenesis for 10 separate medical indications.
I look forward to Zhittya Genesis Medicine soon starting their clinical trial in Parkinson's disease patients. When can we expect a similar announcement from Venturis?
Any more news on Zhittya Genesis Medicine IPO? If they raised mucho dinero in an IPO that would be bad news for Venturis.
Zhittya Genesis Medicine / Venturis Patents. Not often do you see the Chief Financial Officer of a company listed as an inventor. May spell trouble if someone wants to challenge.
Zhittya Genesis Medicine / Venturis Patents. I saw the post on the new Venturis patent - did not recognize the names of the listed inventors. Are they still with Venturis?
Zhittya Regenerative Medicine appears to have found a cooperative regulatory authority in Mexico and will get their trials going soon. What patients are being treated now by Venturis?
Daniel C Montano/Zhittya Genesis Medicine will now reverse the tables and take aim at Venturis and their Directors in the courts. Stay tuned!!
Daniel C Montano and Zhittya Regenerative Medicine headed for victory over Venturis after receiving a favorable ruling from Las Vegas arbitration case!
I've found out that Zhittya Genesis Medicine is developing an intranasal spray for Parkinson's disease. Is Venturis looking at this?
Zhittya Genesis Medicine vindicated by recent court ruling. All the crap about stealing IP from CVBT was bull - CVBT lost 100% of their arguments!
Zhittya Regenerative Medicine scores big legal win. Court case dismissed will allow smooth sailing for Dan Montano and company.
Daniel C Montano speaks in Dubai at Family Offices Summit. Should Venturis be at meetings like these?
Zhittya Genesis Medicine set to treat Parkinson's disease patients in Mexico. They have been given approval to start! Where is Venturis on this?
Daniel C Montano with his newly won judgement will probably be heading to Texas to seize some of those tasty Venturis' assets! Yum, Yum.
Daniel C Montano states that the pre-IPO for the Latin America marketing company will be closing soon - why is Venturis not raising money this way? Why is no one answering these questions?
Zhittya Genesis Medicine has great webinars on their webpage. Where are Venturis' webinars?
Zhittya Genesis Medicine announced that it has been approved to start a clinincal trial in ALS patients in Mexico. Is Venturis pursuing this medical indication? Why is no one from CVBT answering this?
Zhittya Genesis Medicine announced they will starting a Parkinson's disease clinical trial in a few months. What is the status of Venturis (CVBT) study?
I guess Zhittya Genesis Medicine and Daniel Montano will now be taking off and devaluing the position of us CVBT Shareholders. Venturis (CVBT) made it sound like they won the lawsuit!
Daniel C. Montano has won a judgement in excess of $1,000,000, which has been confirmed by the US Federal Court, against Venturis Therapeutics Inc., formerly known as CardioVascular BioTherapeutics, Inc.
The $1,000,000+ judgment was awarded in an arbitration case actually initiated by Venturis against Mr. Montano wherein all but a fraction of Venturis' case was summarily dismissed and Mr. Montano was awarded over $1,000,000 and attorneys' fees and costs.
Daniel Montano is now pursuing the involuntary collections of his judgment against Venturis including judgment debtor discovery against Venturis in order to seize assets from this company to satisfy the judgment.
In other litigation initiated by Venturis against Mrs. Montano, John Laub, and Zhittya, the Nevada State court similarly dismissed all claims brought by Venturis.
April 15, 2021
Zhittya Genesis Medicine
Below is a press release I found on a Zoom webinar that Zhittya is holding called, “Parkinson’s Disease: Therapeutic Angiogenesis as a Disease Modifying, Breakthrough Therapy?”
As a shareholder of CVBT/VT, is this something we're doing?
July 22, 2020 10:30 ET | Source: Zhittya Genesis Medicine Inc
LAS VEGAS, July 22, 2020 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (Zhittya), a private company, announced that it will give a Zoom Webinar on its potential breakthrough therapy to reverse the progression of Parkinson’s disease. Currently, no therapies on the market can halt or reverse this disorder. The webinar will be broadcasted on Monday August 3, 2020 at 1:00 PM Pacific time (4:00 PM Eastern). The webinar is available to all interested parties, free of charge. Zhittya is advancing upon what it believes could be a “disease modifying agent” that has the potential to slow down and possibly even reverse the inexorable decline seen in patients who suffer from this devastating disease.
To register for this webinar go to: zgmwebinars.com
Over the last five years, a new medical hypothesis has been proposed that Parkinson’s disease may be caused by vascular disruption in the areas of the brain which house the “dopamine-producing neurons”, those neurons which are the target of patients suffering from Parkinson’s disease. The concept is simply that the micro-vascularization in the brain is blocked or narrowed restricting the flow of needed blood to these neurons, resulting in the classical symptoms of Parkinson’s disease, including tremor and gait disturbances. Just as in the heart, blockage of coronary arteries can lead to angina and heart attacks, that same process is now thought to underlie the development of Parkinson’s disease.
A new medical imaging technology known as “functional MRI” will be discussed in the webinar and this technology can measure regional blood flow in the brain. Diagnostic imaging data showed diminished blood flow in the area of the brain where the dopamine-producing neurons reside (the substantia nigra region), with Parkinson’s disease patients showing only 50% of the blood flow compared to a healthy younger person. With only 50% of the blood that is needed, why would it be a surprise that those neurons do not perform up to standard?
Zhittya’s management has been developing a biological drug which in other US FDA clinical trials has demonstrated it can trigger “therapeutic angiogenesis” or the growth of new blood vessels in ischemic tissues. In animal studies, monkeys that were given experimental Parkinson’s disease and treated with Zhittya’s biological drug, stopped their motor skills decline and actually improved almost back to their completely normal movement abilities.
Zhittya has been given permission to start a Phase I “proof of concept” clinical trial in Mexico, where three ascending doses of its angiogenesis drug will be studied in patients with Parkinson’s disease. A similar study is under review by regulatory authorities in Estonia. Zhittya has also filed an Investigational New Drug (IND) application with the US FDA to advance its drug into a Phase I clinical trial.
Daniel C. Montano, CEO of Zhittya stated, “I believe we are truly on to something here. Over the last three years, we have continually uncovered data which enhances our belief that therapeutic angiogenesis might be a viable breakthrough treatment for Parkinson’s disease. If, as we believe, Parkinson’s disease is caused by micro-vascular disruption in the brain, we hope our molecule can do in the brain, what it has already demonstrated it can do in the US FDA heart trial, namely, grow new blood vessels.”
Dr. Jack Jacobs, President of Zhittya stated, “Millions of people around the world suffer from Parkinson’s disease. We believe we may have a breakthrough therapy for this disease, which is why we will be spending many millions of dollars to prove if we are right or wrong. In the monkey experiments that were done, our drug demonstrated a genuine disease modifying effect, by regenerating new dopamine neurons in the brain, and it is this activity that we believe led to the restoration of the animal’s motor skills. We do not know if in human clinical trials, the medical outcome will be the same, but what I do know is that we have to find out and we owe this to the millions of sufferers of this horrific disease.”
About Zhittya Genesis Medicine
Zhittya’s management has been working to advance these medicines for over 21 years and many millions of dollars have been expended in preclinical and clinical studies. Zhittya’s medicine initiates a biological process in the human body referred to as “therapeutic angiogenesis” and this process will only occur in diseased tissues that become ischemic due to a lack of blood flow. In those areas with insufficient blood flow, the drug stimulates the growth of new blood vessels, providing nourishment and removing metabolic waste products, thereby re-establishing normal cellular functions. Heart disease, stroke, peripheral artery disease (PAD) and diabetic foot ulcers are just some of the more obvious disorders the drugs can treat, but in fact, over 75 human diseases, including neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease, are thought to be caused by lack of blood flow to a specific tissue.
Zhittya Genesis Medicine Inc., is advancing on COVID-19 treatment!
Look what I found, Zhittya Genesis Medicine is competing with CVBT on COVID-19.
LAS VEGAS, June 17, 2020 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company)(“Zhittya” or the “Company”), announced that its latest White Paper, which details results on its breakthrough medical therapy to potentially treat and reverse lung damage caused by COVID-19, is now available to the public, free of charge. The White Paper is entitled: “COVID-19 Lung Damage – Can Inhaled FGF-1 be a Viable Treatment?”. Zhittya has plans to file an Investigational New Drug (IND) application with the US FDA to advance its drug into a Phase I clinical trial in subjects with lung damage from COVID-19. In parallel, Zhittya also plans to file for an approval to start a Phase I clinical trial for COVID-19 lung damage in Mexico.
As is now being seen in survivors of the COVID-19 pandemic, people who recover can still be left with substantially weakened lung capacity. Physicians are now following the first wave of patients who were discharged from hospitals and up to 30% of these individuals still have respiratory issues. Based on previous flu epidemics, it is estimated that it will take three months to a year or more for a person’s lung function to return to pre-COVID-19 levels, if they ever do return to those levels.
The cells in the lungs which are attacked by the COVID-19 virus are the epithelial cells which line the air sacs in the lung and are directly responsible for the proper exchange of oxygen into the blood circulation. When epithelial cells become damaged either by the virus directly, or through a hyper-response of the body’s immune system, pneumonia and respiratory distress result. If the epithelial cells cannot be regenerated, long-term lung damage and breathing difficulties will persist.
Members of the fibroblast growth factor family, including FGF-1, FGF-2 and FGF-10, are all potent stimulators of lung epithelial cell proliferation and have shown success in reversing lung damage in animal models of viral pneumonia. Zhittya has been developing the FGF-1 biological drug for a number of other medical indications and has received permission from the Mexican FDA to initiate a Phase I trial with FGF-1 in patients with Parkinson’s disease.
Daniel C. Montano, Zhittya’s CEO, stated, “According to the CDC, there are approximately 800,000 annual hospitalizations in the United States for respiratory distress. It is estimated that half of those patients will leave the hospital with some form of lung damage and scarring which can lead to breathing difficulties, especially on exertion. To have a medication available for these patients that could reverse that lung damage, would greatly improve the quality of life for those patients and their care-givers. In addition to helping survivors of COVID-19 with lung damage, we will also determine if our molecule could help patients that suffer respiratory distress from emphysema, COPD and ARDS”.
Dr. Jack Jacobs, President and Chief Science Officer of Zhittya Genesis Medicine, added, “This new addition to Zhittya’s pipeline of drugs currently in development will receive a high priority. A relatively simple protocol can be developed whereby the patient can self-administer the FGF-1 at home and return to the clinic for pulmonary function tests on a defined schedule. Given the excellent safety record FGF-1 has enjoyed when administered to cardiac patients and in wound healing clinical trials, there is no reason not to immediately examine whether this growth factor can heal lungs damaged by COVID-19”.
Zhittya’s White Paper, “COVID-19 Lung Damage – Can Inhaled FGF-1 be a Viable Treatment?” is available to the public free of charge.
About Zhittya Genesis Medicine
Zhittya Genesis Medicine, Inc. is advancing a group of drugs which trigger the human body’s natural regeneration process. Their medicine initiates a biological response in the human body referred to as “therapeutic angiogenesis,” which will only occur in diseased tissues that become ischemic due to a lack of blood flow. In addition, the growth factor acts directly on certain cells in the body, including lung epithelial cells, to stimulate their proliferation in tissue that has become damaged.
Zhittya Genesis Medicine inc
This is the latest news I've found on Zhittya. Is CVBT pursuing this medical indication?
LAS VEGAS, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya” or the “Company”), announced that its latest White Paper, which details results on its breakthrough medical therapy to potentially treat and reverse chronic depression, is now available to the public, free of charge. The White Paper is entitled: “Chronic Depression: Treatable with Therapeutic Angiogenesis?” Zhittya is currently advancing what it believes could be a “disease modifying agent” with the potential to reduce and possibly even reverse the inexorable decline seen in patients who suffer from this devastating disease.
Over the last five years, thanks to the development of more powerful brain imaging systems such as functional MRI, it is now possible to monitor changes in the brain that may be causative factors in major depression. What has emerged from this line of research is that a distinct reduction in blood flow, or perfusion, has been noted in those areas of the brain directly involved in memory, decision making and emotions. This “limbic” area of the brain includes the hippocampus, amygdala and prefrontal cortex.
Even a minor interference in the small capillaries that supply those areas of the brain can materially reduce the amount of blood getting through to the neurons. The hypothesis holds that an impaired micro-vascularization process in the brain restricts the flow of blood needed for these neurons to remain healthy, resulting in the classical symptoms of chronic depression or major depressive disorder.
Zhittya’s management has been developing a biological drug which, in other United States Food and Drug Administration (US FDA) clinical trials, has demonstrated it can trigger “therapeutics angiogenesis” or the growth of new blood vessels in ischemic tissues, or those tissues with reduced blood perfusion. In preclinical studies, this drug has shown the ability to induce angiogenesis, which has also led to new neuron growth, or neurogenesis, in animal models for stroke and Parkinson’s disease.
Zhittya has plans to file an Investigational New Drug (IND) application with the US FDA to advance its drug into a Phase I clinical trial in subjects with chronic depression. In parallel, Zhittya also plans to file for an approval to start a Phase I clinical trial for its chronic depression treatment in Mexico.
Daniel C. Montano, Zhittya’s CEO, stated, “Depression is one of the most prevalent and life-threatening forms of mental illness, affecting roughly 21% of the world’s population and more than 20 million people in the United States alone. A more severe form of the disease known as major depressive disorder, or chronic depression, currently affects more than two million Americans as well. If, as we believe, chronic depression is caused by micro-vascular disruption in the brain, we hope our molecule can do in the brain, what it has already demonstrated it can do in the US FDA heart trial, namely, grow new blood vessels.”
Dr. Jack Jacobs, President and Chief Science Officer of Zhittya Genesis Medicine, added, “Recent brain imaging studies have made it quite evident that chronic depression is associated with pronounced blood perfusion deficits when compared to a healthy individual’s brain scan, especially in the frontal cortex, hippocampus and amygdala areas of the brain, areas associated with mood and emotional control. These findings suggest that a therapeutic agent that can increase blood flow in the brain may be an attractive candidate to test in patients with chronic depression. Our drug, known as human fibroblast growth factor 1, or FGF-1, with its ability to increase blood perfusion by stimulating angiogenesis and neurogenesis, may be an ideal candidate to test in patients with chronic depression.”
“According to a study published in the Western Journal of Medicine by the Seattle-based Center for Health Studies, a number of life-threatening diseases that affect other areas of the body often co-present with major depression. For example, subjects with heart disease suffer a high rate of depression, anywhere from 40% to 65%. Furthermore, 40% of Parkinson’s disease patients, 40% of multiple sclerosis patients, and 25% of diabetics suffer from major depression. We are optimistic that therapeutic angiogenesis may also prove beneficial in treating the depression that is associated with these other disorders.”
Zhittya’s White Paper “Chronic Depression: Treatable with Therapeutic Angiogenesis?” is available to the public free of charge.
About Zhittya Genesis Medicine
Zhittya Genesis Medicine, Inc. is advancing a group of drugs which trigger the human body’s natural regeneration process. Our medicine initiates a biological response in the human body referred to as “therapeutic angiogenesis,” which will only occur in diseased tissues that become ischemic due to a lack of blood flow. In those areas with insufficient blood flow, the drug stimulates the growth of new blood vessels, providing nourishment and removing metabolic waste products, thereby re-establishing normal cellular functions. Heart disease, stroke, peripheral artery disease (PAD) and diabetic foot ulcers are just some of the disorders the drugs can treat. Currently, over 75 human diseases are known to be caused by lack of blood flow to a tissue or organ. The Company’s management has been working to advance its proprietary medicines for over 21 years and has expended in excess of $140 million USD to date in support of these efforts.
I see what you mean. Let's see how this turns out. I'm hoping for the best
Zhittya Genesis Medicine - Another press release I've found on Zhittya. This talks about another investment coming from Latin America
Zhittya certainly looks like they're well funded.
Below is the article:
LAS VEGAS, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya” or the “Company”), has signed a $151.5 million USD international marketing partnership agreement with Regenerative Medicine of Latin America, Inc. for the exclusive rights to market and sell all biological drugs developed by Zhittya during a 30-year time period. The payments include an initial upfront payment valued at $76.5 million with the additional $75 million to be amortized through future milestone payments.
Zhittya is developing a family of biological drugs to treat diseases which are characterized by diminished blood flow, or perfusion, to specific tissues or organs. The diseases Zhittya’s drugs are intended to treat address a variety of disorders and diseases, including: coronary heart disease, diabetic foot ulcers, stroke recovery, Parkinson’s disease (PD), Alzheimer’s disease, and 14 additional major medical disorders characterized by insufficient blood perfusion.
According to the American Heart Association’s 2019 “Statistics at a Glance,” heart disease is responsible for the death of approximately one out of three U.S. adults. In a U.S. Food and Drug Administration (FDA) clinical trial, Zhittya’s heart-specific drug treatment demonstrated a successful triggering of new blood vessel growth in a diseased heart. According to a 2017 report by the World Health Organization, there are an estimated 20 million people who suffer from heart disorders in Latin America alone, 80% of which suffer from a particularly notorious form called ‘small vessel disease,’ a disease that only Zhittya’s drug has been able to address; the standard forms of treatment for coronary artery disease, including bypass and stenting procedures, can only be performed on larger arteries.
“Our portfolio of drugs seeks to address diseases which directly cause the suffering and even death of over 50% of all adults,” said Zhittya CEO Daniel C. Montano. “In addition to the territories covered by our existing partnerships in North America, Europe and China, Latin America is particularly impacted by heart disease due to a variety of health and environmental concerns in the region. This agreement with Regenerative Medicine of Latin America is another major step forward to treating heart disease in Latin America and globally. Going forward, we believe we are on the path to a number of other major medical breakthroughs to address even more diseases caused by a lack of blood perfusion.”
Dr. Jack Jacobs, President of Zhittya Genesis Medicine, stated, “Our drug currently being developed to treat Parkinson’s disease has demonstrated encouraging results with impressive outcomes in preclinical models of Parkinson’s disease in rodents and primates. This drug has the potential to be a ‘disease modifying’ agent; in preclinical studies it was shown to reverse the decline and actually stimulate the regeneration of dopamine-producing neurons, the root cause of Parkinson’s disease in patients. According to a recent report from the Cleveland Clinic, the incidence rate of Parkinson’s disease per 100,000 people was highest in Hispanics. We believe our drug can have a tremendous impact in this region in addition to our existing partnerships both domestically and internationally.”
Dr. Jacobs added, “We have filed applications and are advancing through the approval process to initiate Phase I clinical trials in Mexico for Parkinson’s disease. We are also pursuing a second medical indication for patients with amyotrophic lateral sclerosis (ALS). It is our goal to be in a position to begin dosing patients with Parkinson’s disease and ALS by early 2020, which should enable us to learn if our drug has the same beneficial effects in humans as it demonstrated in animals. These clinical trials that will hopefully begin very soon in Mexico will drive intense attention and interest to Regenerative Medicine of Latin America.”
About Zhittya Genesis Medicine
Zhittya Genesis Medicine, Inc. is advancing a group of drugs which trigger the human body’s natural regeneration process. Our medicine initiates a biological response in the human body referred to as “therapeutic angiogenesis,” which will only occur in diseased tissues that become ischemic due to a lack of blood flow. In those areas with insufficient blood flow, the drug stimulates growth of new blood vessels, providing nourishment and removing metabolic waste products, thereby re-establishing normal cellular functions. Heart disease, stroke, peripheral artery disease (PAD) and diabetic foot ulcers are just some of the disorders the drugs can treat. Currently, over 75 human diseases are known to be caused by lack of blood flow to a tissue or organ. The Company’s management has been working to advance its proprietary medicines for over 21 years and has expended in excess of $140 million USD to date in support of these efforts.
About Regenerative Medicine of Latin America
Regenerative Medicine of Latin America, Inc. owns the 30-year exclusive rights to market and sell all drugs developed by Zhittya for the territories of Mexico and all Latin American countries south of Mexico. These areas encompass a population of over 600 million people. In addition to its vast population, Latin America also has some of the world’s highest rates of diabetes, heart disease, strokes and other diseases brought on by vascular dysfunction.
Here's the latest that I could find on Charlotte's Web.
Below is from the news article:
BOULDER, CO, Jan. 31, 2020 /PRNewswire/ - Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") (TSX:CWEB,OTCQX:CWBHF), the market leader in hemp CBD extract products, today announced management appointments reflecting the Company's distinguished cultivation excellence, as well as its increased activities in public and regulatory affairs, sciences, data and sustainability.
Jared Stanley, Company Co-Founder and Vice President of Cultivation Operations, has been promoted to the newly created role of Chief Cultivation Officer, reporting directly to the Chief Executive Officer, Deanie Elsner. Over the past 6 years, Mr. Stanley has established cultivation excellence for the Company with industry leading expertise. The appointment reflects Mr. Stanley's successful oversight in the execution of every step of the cultivation process. Cultivation is a critical component of the Charlotte's Web supply chain that ensures consistency of high-quality products consumers have come to rely on.
"I am very grateful for this recognition. Cultivation and genetics are the foundation of Charlotte's Web and I am thrilled to be leading it for the organization I helped create" said Mr. Stanley. "It is an area that we have learned to excel in, and our world-class agriculture division continues to cultivate new cannabinoid rich hemp and the higher quality CBD that consumers trust."
Kelly Shea has joined the Company in the newly created role of Senior Vice President of Government Affairs & Corporate Communications, overseeing Federal and State Government Relations, Corporate Social Responsibility, Communications, and Customer Education. Ms. Shea comes to the Company from Danone North America (formerly WhiteWave), where she employed her strong knowledge of agriculture and the legislative environment to advance policies for farmers and food manufacturers to transform the Organic dairy category.
"Much of our growth is heavily influenced by legislative and regulatory decisions and Kelly brings tremendous experience in influencing external environments to embrace new categories," said Ms. Elsner. "Kelly's extensive leadership with organic production and compliance is also a great asset in our ambitions for organic certifications. We employ organic methods on all of our acres with over half our 2019 harvest achieving organic certification."
Paul Lanham, Chief Data, IT and ECommerce Officer, will now report into Deanie Elsner, Chief Executive Officer. Mr. Lanham, oversees the business analytics, digital strategy, and direct-to-the-consumer ecommerce business to bring visibility to operations, enabling better reach and customer service.
Chief Operating Officer, Stephen Lermer, is leaving the Company effective January 31, 2020, returning to his home in Central America to be with family where he will pursue regional opportunities. The Company's vertically integrated supply chain teams assembled under Mr. Lermer will continue their work under the oversight of Chief Financial Officer, Russ Hammer until the new operations leader is announced. The Company extends its gratitude to Mr. Lermer for the competent teams he has built.
"We thank Stephen for his contributions and wish him the best in his future endeavors," said Deanie Elsner, Chief Executive Officer of Charlotte's Web.
About Charlotte's Web Holdings, Inc.
Charlotte's Web Holdings, Inc. is the market leader in the production and distribution of innovative hemp-derived cannabidiol ("CBD") wellness products. Founded by the Stanley Brothers, the Company's premium quality products start with proprietary hemp genetics that are responsibly manufactured into hemp-derived CBD extracts naturally containing a full spectrum of phytocannabinoids, including CBD, terpenes, flavonoids and other beneficial hemp compounds. Charlotte's Web product categories include CBD oil tinctures (liquid products), CBD capsules, CBD topicals, as well as CBD pet products. Charlotte's Web hemp-derived CBD extracts are sold through select distributors, brick and mortar retailers, and online through the Company's website at www.CharlottesWeb.com. The rate the Company pays for agricultural products reflects a fair and sustainable rate driving higher quality yield, encouraging good farming practices, and supporting U.S. farming communities.
Charlotte's Web is a socially conscious company and is committed to using business as a force for good and a catalyst for innovation. The Company weighs sound business decisions with consideration for how its efforts affect its employees, customers, the environment, and the communities where its employees live and where it does business, while maximizing profits and strengthening its brands. The Company's management believes that socially oriented actions have a positive impact on the Company, its employees and its shareholders. Charlotte's Web donates a portion of its pre-tax earnings to charitable organizations.
Shares of Charlotte's Web trade on the Toronto Stock Exchange (TSX) under the symbol "CWEB" and are quoted in U.S. Dollars in the United States on the OTCQX under the symbol "CWBHF". As of January 1, 2020, Charlotte's Web had 67,418,174 Common Shares outstanding and 95,342.49 Proportional Voting Shares convertible at 400:1 into Common Shares, for an effective equivalent of 105,555,170 Common Shares outstanding.
Forward-Looking Information
Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, "forward-looking information"). In some cases, but not necessarily in all cases, forward looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events.
Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the public documents of the Company available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such expectations, estimates, projections and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
Zhittya Genesis Medicine - is this the competitor to Cardio Vascular Bio Therapeutics?
Please see the attached press release on recent funding they've gotten below:
LAS VEGAS, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya” or the “Company”), has signed a $150 million USD international marketing partnership agreement with Regenerative Medicine of China, Inc. for the exclusive rights to market and sell all biological drugs developed by Zhittya during a 30-year time period. The payments include an initial upfront payment valued at $75 million with the additional $75 million to be amortized through future milestone payments.
Zhittya is developing a family of biological drugs to treat diseases which are characterized by diminished blood flow, or perfusion, to specific tissues or organs. The diseases Zhittya’s drugs are intended to treat address a variety of disorders and diseases, including: coronary heart disease, diabetic foot ulcers, stroke recovery, Parkinson’s disease (PD), Alzheimer’s disease, and 14 additional major medical disorders characterized by insufficient blood perfusion.
According to the American Heart Association’s 2019 “Statistics at a Glance”, heart disease is responsible for the death of approximately one out of three U.S. adults. In a U.S. Food and Drug Administration (FDA) clinical trial, Zhittya’s heart-specific drug treatment demonstrated a successful triggering of new blood vessel growth in a diseased heart. According to a 2018 report in the journal, Nature, there are an estimated 40 million people who suffer from heart disorders in China alone, 80% of which suffer from a particularly notorious form called ‘small vessel disease,’ a disease that only Zhittya’s drug has been able to address; the standard forms of treatment for coronary artery disease, including bypass and stenting procedures, can only be performed on larger arteries.
“Our portfolio of drugs seeks to address diseases which directly cause the suffering and even death of over 50% of all adults,” said Zhittya CEO Daniel C. Montano. “China is the most populous country in the world and has some of the worse heart disease problems as well due to smoking, obesity and pollution issues. This agreement with Regenerative Medicine of China is a major step forward to treating heart disease in China, and we believe we are on the path to a number of other major medical breakthroughs to address even more diseases caused by a lack of blood perfusion.”
Dr. Jack Jacobs, President of Zhittya Genesis Medicine, added, “Our drug currently being developed to treat Parkinson’s disease has demonstrated encouraging results with impressive animal treatment data supporting our research efforts. This drug has the potential to be a ‘disease modifying’ agent, as it combats the root cause of Parkinson’s disease in patients. According to a 2019 report in the journal Translational Neurodegeneration, it is estimated that by 2030, Chinese PD patients will increase to over 5 million, accounting for half of the worldwide PD patients. We believe our drug can have a tremendous impact in this region.”
About Zhittya Genesis Medicine
Zhittya Genesis Medicine, Inc. is advancing a group of drugs which trigger the human body’s natural regeneration process. Our medicine initiates a biological response in the human body referred to as “therapeutic angiogenesis,” which will only occur in diseased tissues that become ischemic due to a lack of blood flow. In those areas with insufficient blood flow, the drug stimulates growth of new blood vessels, providing nourishment and removing metabolic waste products, thereby re-establishing normal cellular functions. Heart disease, stroke, peripheral artery disease (PAD) and diabetic foot ulcers are just some of the disorders the drugs can treat. Currently, over 75 human diseases are known to be caused by lack of blood flow to a tissue or organ. The Company’s management has been working to advance its proprietary medicines for over 21 years and has expended in excess of $140 million USD to date in support of these efforts.
About Regenerative Medicine of China
Regenerative Medicine of China, Inc. owns the 30-year exclusive rights to market and sell all drugs developed by Zhittya for the territories of China, Taiwan, Hong Kong and Macao. These areas encompass a population of over 1.4 billion people. With the largest population in the world, China also has some of the world’s highest rates of diabetes, heart disease, strokes and other diseases brought on by vascular dysfunction.
This is interesting. I'll be looking closely into this